Amiodarone-Induced Cirrhosis of Liver: What Predicts Mortality?
Table 2
Characteristics of reported cases.
All cases,
Survivors
Nonsurvivors at 5 months
Median age (years)
68 (56–85)
69.5 (56–83)
67.5 (58–85)
0.84
Male/female
18/12
7/5
11/7
1.00
Diabetes
2
1
0.23
HTN
2
5
1.00
Hyperlipidemia
2
3
1.00
CAD
5
11
0.26
CHF
3
8
0.39
>200 mg/<200 mg Amiodarone dose given
18/12
5/7
13/5
0.33
Latency period
2.92 (0.5–12)
3.06 (0.5–5.5)
2.54 (1–12)
0.45
Cumulative dose
279.92 (55–1241)
279.92 (55–657)
465 (165–1241)
0.07
Prothrombin time
16.76 (11–39)
13.68 (11–17)
18.92 (11–39)
0.08
Bilirubin (micromole/liter)
55.73 (9–481)
71.67 (9–481)
46.16 (12–142)
0.53
AST
177.58 (64–734)
103.33 (38–317)
216.88 (64–734)
0.03
ALK P
352.96 (73–1451)
331.5 (73–1451)
365.59 (119–854)
0.78
Albumin
28 (11–39)
31 (23–39)
26.91 (11–38)
0.32
ALT
134.59 (32–781)
92.1 (32–237)
170 (35–781)
0.16
GGT
569 (133–1493)
640.33 (230–1231)
538.43 (133–1493)
0.74
refers to the number of patients in each group. Not all studies had data on all variables. Median values given for latency period, and for all other variables, mean values are given.
